Johnson & Johnson Oncology +1.8%: Pipeline Drives Stock Rally
Can the rapidly expanding Johnson & Johnson Oncology pipeline secure the company's legendary Dividend King status for the next decade?
Johnson & Johnson Earnings: $21 Billion Swing Ahead of Key Print
Can the upcoming Johnson & Johnson Earnings report justify the healthcare giant's premium valuation after a massive defensive stock rally?
Johnson & Johnson IMAAVY: $24B Revenue Surge in Focus
Can Johnson & Johnson IMAAVY and a $24 billion quarter finally convince investors that JNJ deserves a higher growth multiple?